HealthMore in Health→
Novartis Wants More From Avidity Than Muscular Dystrophy Alone
Novartis says it is looking to apply Avidity Biosciences’ underlying science beyond muscular dystrophies as it works to realize more value from its $12 billion acquisition.
Key Takeaways
- Novartis says Avidity’s science may have uses beyond muscular dystrophies.
- The company tied that view to extracting more value from its $12 billion acquisition.
DE
DT Editorial Team··via endpoints.news